Bristol-Meyers Squibb submits NDA for new formulation of once daily videx(R)(didanosine)
. .(Princeton, NJ, January 31, 2000) -- Bristol-Myers Squibb announced today that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for a new formulation of VIDEX (R), also known as ddI. The new capsules contain enteric coated VIDEX beadlets designed to protect the essential medicine in VIDEX from degrading until it has passed through the stomac...